It is noteworthy that, in addition to the amplification of ERBB2, QIAGEN Clinical Insight® identified “likely pathogenic” mutations in PRDM2 (PR domain zinc finger protein 2; c.3259C>T; [17, 18]), RXRB (retinoid X receptor beta; c.1174C>T), TPR (translocated promoter region, nuclear basket protein; c.6955C>T), and ZNF845 (zinc finger protein 845; c.1831A>T) from 2891 mutations shared in the three lesions (Figs. 3c and 4a), which corroborates the hypothesis that these lesions originated from the same tumor cells. Here, ZNF845 is linked to neoplasm.